Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.68 |
| ▸ | HPGD | P15428 | 1/20 | 0.68 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.66 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.65 |
| ▸ | NPC1 | O15118 | 2/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | RAB9A | P51151 | 1/20 | 0.64 |
| ▸ | CA12 | O43570 | 1/20 | 0.59 |
| ▸ | CA1 | P00915 | 1/20 | 0.59 |
| ▸ | CA2 | P00918 | 1/20 | 0.59 |
| ▸ | CA7 | P43166 | 1/20 | 0.59 |
| ▸ | CA9 | Q16790 | 1/20 | 0.59 |
| ▸ | USP2 | O75604 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.59 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.59 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 2-Naphthaldehyde SCHEMBL27865102 | 0.89 | AKR1C1 (0.61) | TSHRHPGDAKR1C1SIGMAR1NPC1 | |
| SCHEMBL4310722 | 0.88 | TSHR (0.84) | TSHRHPGDAKR1C1NPC1LMNA | |
| SCHEMBL29167317 | 0.86 | LMNA (0.55) | TSHRHPGDAKR1C1SIGMAR1NPC1 | |
| SCHEMBL7218802 | 0.85 | HPGD (0.73) | TSHRHPGDAKR1C1NPC1LMNA | |
| SCHEMBL29941490 | 0.83 | HPGD (0.71) | TSHRHPGDAKR1C1NPC1LMNA | |
| SCHEMBL10197843 | 0.83 | HPGD (0.71) | TSHRHPGDAKR1C1NPC1LMNA | |
| SCHEMBL1588162 | 0.82 | TSHR (0.69) | TSHRHPGDAKR1C1NPC1LMNA | |
| SCHEMBL8358286 | 0.81 | SIGMAR1 (0.76) | TSHRHPGDSIGMAR1LMNAUSP2 | |
| SCHEMBL30250352 | 0.81 | GPR6 (0.54) | TSHRHPGDAKR1C1SIGMAR1NPC1 | |
| SCHEMBL17533885 | 0.81 | TSHR (0.56) | TSHRHPGDAKR1C1NPC1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-114656372-B | P-phenylenediamine bridging compound and application thereof in preparation of medicines for treating sugar metabolism disorder diseases | 广州药本君安医药科技股份有限公司 | 2024-06-18 | — | — | CN | disclosed |
| CN-114573476-B | Linear head-tail diamine bridging compound and application thereof in preparation of medicines for treating sugar metabolic disorder diseases | 广州药本君安医药科技股份有限公司 | 2024-06-11 | — | — | CN | disclosed |
| CN-114656371-B | 1, 4-cyclohexanediamine bridged compounds and their use in the treatment of disorders of glucose metabolism | 广州药本君安医药科技股份有限公司 | 2024-03-12 | — | — | CN | disclosed |
| CN-114656371-A | 1, 4-cyclohexanediamine bridged compound and application thereof in preparing medicament for treating glycometabolism disorder diseases | 广州药本君安医药科技股份有限公司 | 2022-06-24 | — | — | CN | disclosed |
| CN-114656372-A | P-phenylenediamine bridged compound and application thereof in preparation of medicines for treating glycometabolism disorder diseases | 广州药本君安医药科技股份有限公司 | 2022-06-24 | — | — | CN | disclosed |
| CN-114573476-A | Linear head-tail diamine bridged compound and application thereof in preparing medicament for treating glycometabolism disorder diseases | 广州药本君安医药科技股份有限公司 | 2022-06-03 | — | — | CN | disclosed |
| CN-112500314-B | Compound, preparation method thereof and application thereof in preparing medicament for treating glycometabolism disorder diseases | 广州药本君安医药科技股份有限公司 | 2022-05-13 | — | — | CN | disclosed |
| CN-112500314-A | Compound, preparation method thereof and application thereof in preparing medicament for treating glycometabolism disorder diseases | 广州药本君安医药科技股份有限公司 | 2021-03-16 | — | — | CN | disclosed |
| EP-3708169-A1 | 2,3-DIHYDROBENZO[B][1,4]DIOXINE-6-SULFONAMIDE DERIVATIVES HAVING AN ANTICANCER ACTIVITY | Agios Pharmaceuticals, Inc. (US) | 2020-09-16 | — | — | EP | disclosed |
| CN-108623536-B | Substituted o-hydroxybenzene ketone compound and preparation method and application thereof | 浙江省医学科学院 | 2020-05-08 | — | — | CN | disclosed |
| US-7981895-B2 | Histone deacetylase inhibitor; anticancer agents; antiproliferative agents; antitumor agents; psoriasis; piperazine compound containing a carbamic acid group | TOPOTARGET UK LIMITED (GB) | 2011-07-19 | — | — | US | disclosed |
| WO-2010138820-A2 | N,N-DIARYLUREA COMPOUNDS AND N,N'-DIARYLTHIOUREA COMPOUNDS AS INHIBITORS OF TRANSLATION INITIATION | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2010-12-02 | — | — | WO | disclosed |
| EP-1485099-B1 | INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA NV (BE) | 2010-07-07 | — | — | EP | disclosed |
| US-7629343-B2 | Carbamic acid compounds comprising a piperazine linkage as HDAC inhibitors | TOPOTARGET UK LIMITED (GB) | 2009-12-08 | — | — | US | disclosed |
| US-20080269237-A1 | CARBAMIC ACID COMPOUNDS COMPRISING A PIPERAZINE LINKAGE AS HDAC INHIBITORS | TOPOTARGET UK LIMITED (GB) | 2008-10-30 | — | — | US | disclosed |
| EP-1492534-B1 | CARBAMIC ACID COMPOUNDS COMPRISING A PIPERAZINE LINKAGE AS HDAC INHIBITORS | TOPOTARGET UK LTD (GB) | 2008-06-25 | — | — | EP | disclosed |
| US-20050143385-A1 | Carbamic acid compounds comprising a piperazine linkage as hdac inhibitors | TOPOTARGET UK LIMITED (GB) | 2005-06-30 | — | — | US | disclosed |
| EP-1492534-A1 | CARBAMIC ACID COMPOUNDS COMPRISING A PIPERAZINE LINKAGE AS HDAC INHIBITORS | TopoTarget UK Limited (GB) | 2005-01-05 | — | — | EP | disclosed |
| WO-2003082288-A1 | CARBAMIC ACID COMPOUNDS COMPRISING A PIPERAZINE LINKAGE AS HDAC INHIBITORS | TOPOTARGET UK LIMITED (GB) | 2003-10-09 | — | — | WO | disclosed |
| WO-2003075929-A1 | INHIBITORS OF HISTONE DEACETYLASE | JANSSEN PHARMACEUTICA N.V. (BE) | 2003-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143385-A1 | Carbamic acid compounds comprising a piperazine linkage as hdac inhibitors | HDAC1, HDAC7, HDAC11 | TSHR 4057/4885HPGD 1108/4885AKR1C1 619/4885 |
| US-20080269237-A1 | CARBAMIC ACID COMPOUNDS COMPRISING A PIPERAZINE LINKAGE AS HDAC INHIBITORS | HDAC5, HDAC1, HDAC7 | TSHR 3923/4885HPGD 1325/4885AKR1C1 2613/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.